The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 1,346 studies for Liver Neoplasms across more than 10 countries. 335 are recruiting or about to start. 534 of them are mainly about Liver Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Carcinoma, Hepatocellular: 4,480 studies, 1,303 open.
ClinicalTrials.gov finds 5,499 studies for Liver Neoplasms.How that becomes 1,346 here
This page counts the studies the registry files under Liver Neoplasms, and those it files under no condition that list Liver Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count
5,499Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−37List Liver Neoplasms as a condition, but the registry did not file them under itMost often written as “Colon Cancer Liver Metastasis” (10), “Recurrent Childhood Liver Cancer” (7), and “Colorectal Cancer Liver Metastasis” (4). The registry filed them under other conditions only, most often Colorectal Neoplasms (14) and Colonic Neoplasms (9).
−1,231Match it another way135 name it in the title, 13 in a keyword, and 1,083 by a synonym or other text the search reads.
1,346The count on this page52 of them list Liver Neoplasms in their own words; the registry filed them under no condition.
Every program with a company-led study here in the last two years, whatever its size: 14 programs from 12 companies, 4 with this as their studies’ main aim; 1 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Nanjing Sanhome Pharmaceutical, AbbVie and Beijing Biotech here →
Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.
Comparator & background therapies
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
The 14 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (4)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
1 Jan 2027 est.SL-28· Second Life Therapeutics · Phase 2named, not the main aimNCT07341737 SL-28 for Advanced Solid Tumours — primary endpoint: Number of participants with treatment-emergent adverse events · 60 enrolled
14 Mar 2027 est.EB-G3B7-NK dual-target CAR-NK cells· Beijing Biotech · Phase 2main aimstudied with fludarabinestudied with CyclophosphamideNCT07500220 Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC — primary endpoint: Incidence of dose-limiting toxicities (DLTs) · 30 enrolled
30 Jun 2027 est.Autologous immune Cells· Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. · Phase 2named, not the main aimNCT07260058 Immune Cell Therapy for Advanced Solid Tumors — primary endpoint: Phase II Primary Outcome: Objective Response Rate (ORR) · 48 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Liver Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
109studies finish main data collection within a year3 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 243 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 69 (28%) stop at 75 or younger. 14 (6%) take children under 18. 1 (<1%) are for women only and 0 (0%) for men only; 34 (14%) take healthy volunteers.
Across all 1,346 studies, recruiting or not: 20% stop at 75 or younger and 4% at 65; 8% take children; <1% are for women only and <1% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Liver Neoplasms studies take
Of 99 phase 1 interventional studies under Liver Neoplasms, half reached primary completion within 49 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
49 mo32–65 · 99 studies
49 mo28–66 · 51 studies
51 mo33–63 · 48 studies
Phase 1/2
59 mo44–72 · 33 studies
—
—
Phase 2
57 mo37–100 · 86 studies
—
65 mo37–103 · 72 studies
Phase 3
57 mo38–97 · 30 studies
—
—
Interventional, no phase
39 mo18–73 · 168 studies
—
44 mo18–82 · 149 studies
Observational
59 mo34–172 · 160 studies
—
114 mo34–172 · 132 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.